ICON plc Ordinary Shares (ICLR)
Stock · NASDAQ · Health Care
$170.19as of 10/16/2026
Price chart
Active signals
ICLR Signal Track Record
How signals performed across all stocks →What ICLR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | +2.7% | 55% | September 17, 2026 |
| Bollinger Band Breakdown | 20 | +1.2% | 55% | August 3, 2026 |
| Bollinger Band Breakout | 19 | -1.9% | 42% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -2.8% | 31% | June 8, 2026 |
| Any 20-session window (baseline) | +0.1% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinic…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 40,200
- Website
- www.iconplc.com/
Fundamentals
- 1-day range
- $166.94$177.2
- Market cap
- $12.34B
- P/E (trailing)
- 190.41
- P/E (forward)
- 14.86
- EPS (trailing)
- $0.90
- Dividend yield
- —
- Beta
- 1.22
- Avg. volume
- 846.4K
Forecasts
17 analyst ratings
ICON plc Ordinary Shares Competitors
Chosen by industry and closest market cap.
- ICLRICON plc Ordinary Shares$170.18▼ 2.83%Market cap $12.34BP/E 190.41$66.57$203.91
- CRLCharles River Laboratories International Inc. Common Stock$300.15▼ 1.99%Market cap $12.79BP/E —$146.2$333.3
- MEDPMedpace Holdings Inc. Common Stock$618.47▼ 1.61%Market cap $16.33BP/E 35.88$373$677.9
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
- INCYIncyte Corp. Common Stock$113.07▼ 0.18%Market cap $24.00BP/E 14.30$84.02$132.6
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ICLR ICON plc Ordinary Shares | $12.34B | 190.41 | $170.18 | ▼ 2.83% | $66.57$203.91 |
| CRL Charles River Laboratories International Inc. Common Stock | $12.79B | — | $300.15 | ▼ 1.99% | $146.2$333.3 |
| MEDP Medpace Holdings Inc. Common Stock | $16.33B | 35.88 | $618.47 | ▼ 1.61% | $373$677.9 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
| INCY Incyte Corp. Common Stock | $24.00B | 14.30 | $113.07 | ▼ 0.18% | $84.02$132.6 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Here's How Much $1000 Invested In Icon 20 Years Ago Would Be Worth Todaybenzinga · 10/14/2026
- ICON Schedules Third Quarter 2026 Earnings Conference CallYahoo · 10/8/2026
- 'HHS launches project to speed up clinical trials' - AxiosBenzinga · 9/30/2026
- UBS Reinstates Neutral on Icon, Announces $195 Price TargetBenzinga · 9/30/2026
- ICON Public Limited Company’s (ICLR) Shrinking Moat Warranted an Early DepartureYahoo · 9/22/2026
- Strategic Sale: DR JOHN CLIMAX Decides To Exercise Options Worth $204K At IconBenzinga · 9/18/2026
- Options Exercise: Pacelli Eugene McCague At Icon Realizes $132KBenzinga · 9/18/2026
- Martin Ronan Murphy Exercises Options, Realizes $204KBenzinga · 9/18/2026
- Citigroup Maintains Neutral on Icon, Lowers Price Target to $175Benzinga · 9/18/2026
Insider Activity
Insider Actions →- Eugene Pacelli McCague · September 17, 2026 · Option Exercise3.3K @ $125.74
- Eugene Pacelli McCague · September 17, 2026 · Sale3.3K @ $175
- Ronan Martin Murphy · September 17, 2026 · Option Exercise5.0K @ $125.74
- Ronan Martin Murphy · September 17, 2026 · Sale5.0K @ $175
- John Dr Climax · September 16, 2026 · Option Exercise5.0K @ $125.74
- John Dr Climax · September 16, 2026 · Sale5.0K @ $175
- Ciaran Murray · August 11, 2026 · Sale305 @ $163.77
- Ciaran Murray · August 11, 2026 · Sale280 @ $162.72
- Linda Grais · August 11, 2026 · Sale87 @ $162.72
- John Dr Climax · August 11, 2026 · Sale67 @ $165.51
- John Dr Climax · August 11, 2026 · Sale591 @ $164.47
- John Dr Climax · August 11, 2026 · Sale95 @ $163.77
- John Dr Climax · August 11, 2026 · Sale88 @ $162.72
- Nigel Bernard John Clerkin · August 11, 2026 · Sale180 @ $165.51
- Nigel Bernard John Clerkin · August 11, 2026 · Sale1.6K @ $164.47
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Icon plc (ICLR) gets new US trial boost and UBS price target update
Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.
Icon plc (ICLR) gets new US trial boost and UBS price target update. Icon plc is highlighted by a U.S. Health and Human Services project aimed at speeding up clinical trials, which could improve the pace of its drug development. UBS has lifted its rating to neutral and set a $195 target, reflecting confidence in the company’s prospects. The stock sits near a key support level and shows a mild RSI, indicating moderate purchase pressure. These developments suggest increased attention from analysts and potential for short‑term volatility.